Join the Budesonide group to help and get support from people like you.
Budesonide News
Related terms: Budesonide Nasal
FDA Approves Eohilia (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis
OSAKA, Japan and CAMBRIDGE, Massachusetts, February 12, 2024 – Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved Eohilia (budesonide oral s...
Calliditas Therapeutics Announces Full FDA Approval of Tarpeyo, the Only FDA-Approved Treatment for IgA Nephropathy to Significantly Reduce the Loss of Kidney Function
December 20, 2023 Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), today announced that the U.S. Food and Drug Administration (FDA) has approved Tarpeyo (budesonide) ...
Budesonide Yields Durable Reduction in eGFR for IgA Nephropathy
MONDAY, Aug. 21, 2023 – For patients with immunoglobulin A (IgA) nephropathy, nine months of treatment with targeted-release formulation of budesonide (Nefecon) yields a greater reduction in...
Studies Explore Risks for Exposure to Antenatal Corticosteroids
WEDNESDAY, Aug. 9, 2023 – Exposure to antenatal corticosteroids is associated with serious infection in children and with increased short- and long-term adverse health outcomes, according to two...
FDA Approves Tarpeyo (budesonide) to Reduce Proteinuria in IgA Nephropathy
STOCKHOLM, Dec. 15, 2021 /PRNewswire/ – Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the US Food and Drug Administration (FDA) has approved...
FDA Approves Uceris (budesonide) Rectal Foam for Ulcerative Colitis
RALEIGH, N.C., October 8, 2014 – Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Food and Drug Administration (FDA) has granted final approval for Uceris (budesonide) rectal foam...
FDA Medwatch Alert: The Compounding Shop: FDA News Release - Lack of Sterility Assurance of Drug Products
UPDATED 09/27/2013. FDA alerted patients and health care providers that budesonide solution, used for nasal irrigation, from The Compounding Shop may be contaminated and should not be used or a...
Santarus Receives FDA Approval of Uceris (budesonide) for the Induction of Remission in Patients with Active, Mild to Moderate Ulcerative Colitis
SAN DIEGO--(BUSINESS WIRE)--Jan 15, 2013 - Santarus, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Uceris (budesonide) extended release tablets for the induction...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Crohn's Disease, Asthma - Maintenance, Asthma, Crohn's Disease - Maintenance, Inflammatory Bowel Disease, Ulcerative Colitis